Recombinant MAM from Faecalibacterium duncaniae exhibits a protective effect in DNBS-induced colitis
These findings provide a critical validation step for the therapeutic potential of MAM in intestinal inflammation, despite its purification under denaturing conditions. Future studies should focus on optimizing protein stability and conformational integrity to increase its therapeutic potential as a biotherapeutic agent.
Authors
- Laura Creusot (ORCID: https://orcid.org/0000-0002-3882-8423)
- Thaís Cristina Vilela Rodrigues (ORCID: https://orcid.org/0000-0002-2048-5522)
- Jean‐Marc Chatel
- Luis G. Bermúdez‐Humarán (ORCID: https://orcid.org/0000-0001-7525-3131)
- Anne Aucouturier (ORCID: https://orcid.org/0000-0002-8587-1969)
- Luís Cláudio Lima de Jesus (ORCID: https://orcid.org/0000-0001-7708-3033)
- Philippe Langella (ORCID: https://orcid.org/0000-0001-5960-4341)
- Nathalie Rolhion (ORCID: https://orcid.org/0000-0002-2946-4808)
- Monique Ferrary Américo (ORCID: https://orcid.org/0000-0002-6501-9533)
- Vasco Azevedo (ORCID: https://orcid.org/0000-0002-4775-2280)
Institutions
- Universidade Federal de Minas Gerais (BR)
- Inserm (FR)
- Université Paris-Saclay (FR)
- Microbiologie de l’alimentation au service de la santé (FR)
- Sorbonne Université (FR)
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR)
- Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine (FR)
- Centre de Recherche Saint-Antoine (FR)
Publication Details
- Journal
- Microbial Cell Factories
- Published
- 2025-12-06
- DOI
- https://doi.org/10.1186/s12934-025-02877-9
- Primary Topic
- Polysaccharides and Plant Cell Walls
- Type
- article
- Field-Weighted Citation Impact
- 0.00